Barclays PLC Increases Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA)

Barclays PLC lifted its holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA) by 210.6% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 45,110 shares of the company’s stock after acquiring an additional 30,585 shares during the period. Barclays PLC owned 0.12% of Entrada Therapeutics worth $720,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. The Manufacturers Life Insurance Company raised its position in Entrada Therapeutics by 3.9% during the second quarter. The Manufacturers Life Insurance Company now owns 57,098 shares of the company’s stock valued at $814,000 after purchasing an additional 2,146 shares during the period. US Bancorp DE purchased a new stake in Entrada Therapeutics during the 3rd quarter valued at $42,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in Entrada Therapeutics by 34.7% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 14,156 shares of the company’s stock worth $226,000 after buying an additional 3,644 shares during the last quarter. Rhumbline Advisers lifted its position in Entrada Therapeutics by 25.3% in the second quarter. Rhumbline Advisers now owns 36,940 shares of the company’s stock worth $526,000 after buying an additional 7,452 shares during the last quarter. Finally, Public Employees Retirement System of Ohio boosted its stake in Entrada Therapeutics by 89.1% during the third quarter. Public Employees Retirement System of Ohio now owns 16,259 shares of the company’s stock worth $260,000 after buying an additional 7,659 shares during the period. Hedge funds and other institutional investors own 86.39% of the company’s stock.

Entrada Therapeutics Stock Performance

Entrada Therapeutics stock opened at $17.29 on Wednesday. The company has a market capitalization of $646.99 million, a PE ratio of 10.87 and a beta of -0.18. The company has a 50 day moving average price of $18.54 and a 200-day moving average price of $16.78. Entrada Therapeutics, Inc. has a fifty-two week low of $11.35 and a fifty-two week high of $21.79.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on TRDA. Roth Mkm began coverage on shares of Entrada Therapeutics in a research note on Thursday, December 5th. They issued a “buy” rating and a $29.00 target price on the stock. Roth Capital raised shares of Entrada Therapeutics to a “strong-buy” rating in a research report on Thursday, December 5th. HC Wainwright boosted their target price on Entrada Therapeutics from $18.00 to $20.00 and gave the company a “buy” rating in a research report on Wednesday, November 6th. Finally, Oppenheimer increased their price target on Entrada Therapeutics from $25.00 to $28.00 and gave the stock an “outperform” rating in a report on Wednesday, November 6th.

Insiders Place Their Bets

In other news, CFO Kory James Wentworth sold 8,637 shares of the company’s stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $19.98, for a total value of $172,567.26. Following the completion of the sale, the chief financial officer now owns 73,849 shares of the company’s stock, valued at approximately $1,475,503.02. This represents a 10.47 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Bioventures 2018 L.P. Mpm sold 22,935 shares of the stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $20.77, for a total transaction of $476,359.95. Following the transaction, the insider now owns 4,402,849 shares in the company, valued at approximately $91,447,173.73. This represents a 0.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 42,281 shares of company stock worth $861,999 in the last ninety days. 7.59% of the stock is owned by company insiders.

Entrada Therapeutics Company Profile

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.